NCT04453189View on ClinicalTrials.gov

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

September 14, 2020

Study Completion Date

September 14, 2020

Conditions
Healthy Participants
Interventions
DRUG

JNJ-64417184

Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.

DRUG

Lansoprazole

Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.

DRUG

Famotidine

Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.

Trial Locations (1)

9728 NZ

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04453189 - A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants | Biotech Hunter | Biotech Hunter